{"slideshow_credits": null, "snippet": "The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to treat rare diseases.", "abstract": "Alexion Pharmaceuticals says it will buy Synageva BioPharma for about $8.4 billion; firm specializes in rare diseases, with new drug launching in 2015.", "section_name": "Business Day", "print_page": "9", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/05/07/business/dealbook/alexion-to-buy-synageva-biopharma-in-8-4-billion-deal.html", "lead_paragraph": "The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to treat rare diseases.", "headline": {"main": "Alexion\u00a0to Buy Synageva BioPharma in $8.4 Billion Deal", "print_headline": "Alexion, Maker of a Rare-Disease Drug, Buys Another"}, "_id": "554a2ed738f0d838fba7397c", "word_count": "727", "multimedia": [{"height": 126, "url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 422, "url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/05/07/business/07db-drug-web/07db-drug-web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "422"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-05-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Alexion Pharmaceuticals Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Synageva BioPharma Corp", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Biotechnology and Bioengineering", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}